INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 9.08 billion by 2030 | 6% | North America |
| by Form | by Drug Class | by Emetogenik Risk |
|---|---|---|
|
|
|
SCOPE OF THE REPORT
Market Overview
The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market size is projected to grow from USD 6.04 billion in 2023 to USD 9.08 billion by 2030, exhibiting a CAGR of 6% during the forecast period.
Chemotherapy Induced Nausea and Vomiting (CINV) medicines are pharmaceuticals that are especially developed to relieve the symptoms of nausea and vomiting that frequently accompany cancer chemotherapy treatment. Chemotherapy medications can irritate the stomach lining and stimulate the release of specific substances in the body, resulting in nausea and vomiting. CINV medicines attempt to avoid or lessen these side effects, improving the overall quality of life for cancer patients receiving chemotherapy. There are several types of CINV medications, including antiemetic’s such as serotonin receptor antagonists, dopamine receptor antagonists, and NK1 receptor antagonists. These drugs operate by targeting particular receptors in the brain and gastrointestinal system, so disrupting the impulses that cause nausea and vomiting. By properly treating these adverse effects, CINV medicines help patients endure their chemotherapy regimens and stick to their treatment goals. The precise chemotherapy medications being used, the individual patient’s vulnerability to nausea and vomiting, and the overall treatment plan created by the healthcare team all influence the selection of CINV treatments.
The market for Chemotherapy Induced Nausea and Vomiting (CINV) medications is critical due to its enormous influence on the well-being of cancer patients receiving chemotherapy. Chemotherapy, while necessary for cancer treatment, frequently causes severe side effects such as nausea and vomiting, which can drastically reduce a patient’s quality of life and hamper treatment completion. The CINV medicines industry plays an important role in resolving these difficulties by delivering pharmacological treatments especially tailored to control and relieve these severe symptoms. Effective CINV medicines not only improve the overall patient experience during chemotherapy, but they also help with treatment adherence. Patients who can tolerate their chemotherapy regimens better are more likely to finish the course, increasing the likelihood of good cancer treatment results. The market for CINV pharmaceuticals is thus critical in ensuring that cancer patients have access to a variety of effective therapies suited to their specific requirements, hence reducing the negative impact of treatment side effects. Furthermore, continuous research & development in this market aims to increase the efficacy and safety of CINV medications, strengthening their role in helping cancer patients throughout their treatment journey. The market for Chemotherapy Induced Nausea and Vomiting (CINV) medications is large and important in cancer care. As the worldwide cancer burden increases, so will the demand for effective CINV medicines. The market includes a wide range of medications used to prevent and treat nausea and vomiting caused by various chemotherapy regimens. Drugs that target various receptors in the central nervous system and gastrointestinal tract are included. The scope also includes both acute and delayed stages of CINV, addressing the requirement for comprehensive care throughout the chemotherapeutic course. Research & development advances contribute to the CINV medicines market is rising breadth, with continued attempts to produce unique formulations, better drug delivery systems, and increase the overall efficacy of antiemetic medications. Furthermore, the market comprises a wide range of medication combinations that are customized to specific chemotherapy procedures and patient profiles.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2030 |
| Base year | 2022 |
| Estimated year | 2023 |
| Forecasted year | 2023-2030 |
| Historical period | 2019-2021 |
| Unit | Value (USD Billion) (Thousand Units) |
| Segmentation | By Form, By Drug Class, By Emetogenik Risk and Region |
| Â
By  Form |
|
| Â
By Drug Class |
|
| By Emetogenik Risk |
|
| Â
 By Region  |
|
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market Segmentation Analysis
The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market is bifurcated three segments, by form, drug class and region. By form, the market is bifurcated into market injectable, oral, transdermal patches. By drug class, the market is bifurcated 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, others and region.
The Chemotherapy Induced Nausea and Vomiting (CINV) medicines market is divided into injectable, oral and transdermal patches. Injectable formulations often entail intravenous or subcutaneous injection, allowing for the quick and direct delivery of antiemetic medicines into the circulation. These are frequently used in clinical settings to treat acute bouts of CINV during and immediately after chemotherapy regimens. Oral formulations provide a simple and patient-friendly alternative to tablet or liquid medicine administration. This method is especially useful in outpatient settings and home-based therapy since it provides flexibility and convenience of administration. Patients can stick to their treatment programs more easily, improving overall treatment compliance. Transdermal patches are yet another novel method of CINV medication. These patches administer antiemetic medicines via the skin, allowing for regulated and sustained release over time. This technique is intended to address the delayed phase of CINV, giving long-term relief after the first post-chemotherapy period. Transdermal patches have the advantage of allowing for less frequent dosage, which may lead to greater patient comfort and adherence. The many forms in the CINV medicines market respond to the various requirements and preferences of patients, giving healthcare practitioners flexibility in adjusting treatments to particular circumstances. The availability of various administration choices not only improves the overall patient experience, but also shows the pharmaceutical industry’s continued efforts to create comprehensive and patient-centered solutions for addressing chemotherapy-induced adverse effects.
Medication class classifies the CINV medicines market, with important categories including 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and others. 5-HT3 receptor antagonists, such as ondansetron and granisetron, act by inhibiting serotonin receptors in the central nervous system, thereby reducing chemotherapy-induced nausea and vomiting. Neurokinin-1 receptor antagonists, such as aprepitant, target a different route by inhibiting the function of substance P, a neurotransmitter implicated in nausea and vomiting. These medications are frequently used in conjunction with 5-HT3 receptor antagonists to give a more complete approach to CINV therapy. Corticosteroids, such as dexamethasone, possess anti-inflammatory properties and are known for their ability to reduce chemotherapy-induced inflammation and mitigate nausea and vomiting. They are often used as part of combination therapy with other antiemetic agents. Cannabinoids, derived from the cannabis plant or synthetic sources, have shown promise in managing CINV, particularly when other antiemetic options may be insufficient. These drugs act on the endocannabinoid system to modulate nausea and vomiting responses. The category labeled as ‘others’ encompasses additional classes of drugs that may include dopamine receptor antagonists, benzodiazepines, and antihistamines, among others. These drugs may be used in specific circumstances or in combination with the major classes indicated above to address a variety of patient requirements and chemotherapy-induced effects.
Medication class to represent the many mechanisms and pathways targeted by pharmacological treatments to successfully manage nausea segments the CINV medicines market and vomiting associated with chemotherapy. This comprehensive approach enables healthcare practitioners to adjust treatment plans based on individual patient profiles and the unique obstacles offered by diverse chemotherapy regimens.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market Dynamics
Driver
Advances in chemotherapy therapies, such as the discovery of new and more effective medicines, may increase the prevalence of CINV, boosting demand.
The chemotherapy treatment landscape has undergone constant developments, with the introduction of new and stronger medications aimed at battling various forms of cancer. These advances in cancer therapies have resulted in increased efficacy in targeting malignant cells, hence improving treatment results. However, one unexpected effect of these powerful chemotherapy medicines is a greater probability of patients developing Chemotherapy-Induced Nausea and Vomiting (CINV). As chemotherapy treatments grow more focused and effective in their anti-cancer actions, they can also cause the production of chemicals that excite the vomiting center in the brain, resulting to an increase in the prevalence of CINV. The intricacy of the molecular pathways involved in these advanced chemotherapy regimens contributes to the difficulties in successfully predicting and controlling CINV. Patients getting these cutting-edge therapies may be more likely to have nausea and vomiting as side effects, lowering their quality of life during and after treatment. In response to this rising worry, there is a corresponding need for breakthroughs in the development of efficient antiemetic medications intended particularly to address CINV associated with these current chemotherapy agents. The intricate association between advances in chemotherapy treatments and the following rise in CINV emphasizes the significance of a comprehensive approach to cancer care. It is critical to balance the benefits of powerful anti-cancer medicines with the requirement for appropriate supportive care, including effective antiemetic drugs, in order to improve overall patient experience and treatment adherence. Addressing the issues provided by CINV in the context of cutting-edge chemotherapeutic therapies remains an important part of comprehensive cancer management as the field of oncology evolves.
Restraint
The treatment of Chemotherapy-Induced Nausea and Vomiting (CINV) is complicated by the low effectiveness of available antiemetic medicines in some individuals.
Despite advances in medicines aimed at alleviating this terrible side effect of chemotherapy, a fraction of cancer patients may not find total relief from nausea and vomiting with the treatments now available. This restriction highlights the crucial need for new effective CINV therapy alternatives. Individual reactions to antiemetic medications vary, highlighting the complicated and multifaceted nature of CINV. Factors like as the specific chemotherapy regimen, patient characteristics, and differences in the emetogenic potential of different anticancer drugs all contribute to the varying nature of this side effect. Some patients may discover that existing antiemetic drugs are insufficient in giving appropriate relief, resulting in the persistence of CINV symptoms, which can have a substantial impact on their quality of life during and after chemotherapy. The significant effects that prolonged nausea and vomiting may have on patients’ physical well-being, mental condition, and overall adherence to cancer therapy underscores the need for more effective CINV therapies. Inadequate CINV management may not only impair the patient’s capacity to tolerate chemotherapy, but it may also lead to a bad view of the treatment experience, thereby affecting treatment continuance and results.
Opportunities
Opportunities exist for the development of targeted therapies that address specific pathways involved in CINV, providing more precise and effective management while minimizing side effects.
The development of specific medicines provides a great possibility in tackling Chemotherapy-Induced Nausea and Vomiting (CINV), providing a more specific and effective approach to management while limiting undesired side effects. Traditional antiemetic medicines frequently act widely on many receptors, resulting in possible adverse effects and varying effectiveness between people and chemotherapy regimens.
Targeted therapy, on the other hand, concentrate on specific biochemical processes or receptors implicated in the development of CINV. These medicines can give a more personalized and efficient response by focusing on these specific targets, lowering the incidence and severity of nausea and vomiting associated with chemotherapy. This method not only improves the overall efficacy of CINV care, but it also reduces the chance of side consequences that might jeopardize a patient’s well-being.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market Trends
-
The market for CINV medicines is being influenced by the push toward customized treatment. Antiemetic medications are being tailored to specific patient factors such as genetics, general health state, and nausea susceptibility. This method tries to improve treatment outcomes while minimizing side effects.
-
Ongoing research and development initiatives are aimed at developing innovative CINV medication formulations. This involves the creation of extended-release formulations, transdermal patches, and alternate delivery modalities to improve therapeutic efficacy, patient compliance, and convenience.
-
Combination therapy incorporating several antiemetic medication types are increasingly being investigated by healthcare practitioners. Combinations of 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, and corticosteroids, for example, are being employed to give more complete and effective management of CINV over many stages.
-
The role of supportive care in cancer therapy is becoming better recognized. To meet the holistic requirements of cancer patients, CINV medications are being integrated into complete supportive care regimens that may include dietary assistance, psychiatric therapies, and symptom management.
-
The investigation of cannabis for the treatment of CINV is gaining attention. Cannabinoids may become more commonly utilized in combination with existing antiemetic’s to give further relief for patients as more research on their potential advantages and safety is undertaken.
Competitive Landscape
The competitive landscape of the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market was dynamic, with several prominent companies competing to provide innovative and advanced Chemotherapy Induced Nausea and Vomiting (CINV) Drugs solutions.
- Amneal Pharmaceuticals
- Kyowa Kirin
- Tesaro
- Acacia Pharma
- Heron Therapeutics
- Cadila Pharmaceuticals Limited
- Helsinn Holding S.A.
- Insys Therapeutics
- GlaxoSmithKline plc
- Merck & Co.
- Eisai Co., Ltd
- Hoffmann-La Roche Ltd.
- Sandoz
- Cipla Ltd
- Orchid Pharma Ltd
- AdvaCare Pharma
- Mundipharma
- Cinfa Biotech
- Oncobiologics
- Mylan N.V.
Recent Developments:
January 18, 2023 –Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced the launch of Cippoint, a point- of-care testing device.
December 22, 2023- Merck, known as MSD outside of the United States and Canada, (NYSE: MEK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
Regional Analysis
North America, primarily the United States, holds a market share of over 38% in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market as of 2023.
The United States has a large cancer burden, with an estimated 1.9 million new cancer cases diagnosed in 2023. The rising number of cancer patients undergoing chemotherapy stimulates the market for CINV medicines. North America has a well-developed healthcare system with extensive access to specialist cancer care and effective CINV prevention and treatment techniques. In North America, private and public health insurance coverage frequently covers CINV prescription expenses, making them more accessible to patients than in other locations.
Target Audience for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market
- Pharmaceutical Companies
- Healthcare Professionals
- Hospitals and Clinics
- Patients and Caregivers
- Research and Academic Institutions
- Regulatory Authorities
- Health Insurance Providers
- Investors and Financial Institutions
- Patient Advocacy Groups
- Distribution and Supply Chain Partners
Segments Covered in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market Report
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by Form
- Injectable
- Oral
- Transdermal Patches
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by Drug Class
- 5-HT3 Receptor Antagonists
- Neurokinin-1 Receptor Antagonists
- Corticosteroids
- Cannabinoids
- Others
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by Emetogenik Risk
- Highly Emetogenic Chemotherapy (HEC)
- Moderately Emetogenic Chemotherapy (MEC)
- Low Emetogenic Chemotherapy (LEC)
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Key Question Answered
- What is the expected growth rate of the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market over the next 7 years?
- Who are the key market participants inChemotherapy Induced Nausea and Vomiting (CINV) Drugs , and what are their market share?
- What are the end-user industries driving market demand and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, the Middle East, and Africa?
- How is the economic environment affecting the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?
- What is the current and forecasted size and growth rate of the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?
- What are the key drivers of growth in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?
- Who are the major players in the market and what is their market share?
- What are the distribution channels and supply chain dynamics in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?
- What are the technological advancements and innovations in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?
- What are the product offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA TYPES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET OUTLOOK
- GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- INJECTABLE
- ORAL
- TRANSDERMAL PATCHES
- GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- 5-HT3 RECEPTOR ANTAGONISTS
- NEUROKININ-1 RECEPTOR ANTAGONISTS
- CORTICOSTEROIDS
- CANNABINOIDS
- OTHERS
- GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)
- MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
- LOW EMETOGENIC CHEMOTHERAPY (LEC)
- GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY REGION, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES*
(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)
- AMNEAL PHARMACEUTICALS
- KYOWA KIRIN
- TESARO
- ACACIA PHARMA
- HERON THERAPEUTICS
- CADILA PHARMACEUTICALS LIMITED
- HELSINN HOLDING S.A.
- INSYS THERAPEUTICS
- GLAXOSMITHKLINE PLC
- MERCK & CO.
- EISAI CO., LTD
- HOFFMANN-LA ROCHE LTD.
- SANDOZ
- CIPLA LTD
- ORCHID PHARMA LTD
- ADVACARE PHARMA
- MUNDIPHARMA
- CINFA BIOTECH
- ONCOBIOLOGICS
- MYLAN N.V.
*THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 2 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 3 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 4 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 5 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 6 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 7 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY REGION (USD BILLION) 2020-2030
TABLE 8 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY REGION (THOUSAND UNITS) 2020-2030
TABLE 9 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 10 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 11 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 12 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 13 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 14 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 15 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 16 NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 17 US CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 18 US CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 19 US CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 20 US CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 21 US CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 22 US CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 23 CANADA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 24 CANADA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 25 CANADA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 26 CANADA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 27 CANADA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 28 CANADA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 29 MEXICO CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 30 MEXICO CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 31 MEXICO CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 32 MEXICO CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 33 MEXICO CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 34 MEXICO CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 35 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 36 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 37 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 38 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 39 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 40 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 41 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 42 SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 43 BRAZIL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 44 BRAZIL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 45 BRAZIL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 46 BRAZIL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 47 BRAZIL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 48 BRAZIL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 49 ARGENTINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 50 ARGENTINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 51 ARGENTINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 52 ARGENTINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 53 ARGENTINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 54 ARGENTINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 55 COLOMBIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 56 COLOMBIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 57 COLOMBIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 58 COLOMBIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 59 COLOMBIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 60 COLOMBIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 61 REST OF SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 62 REST OF SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 63 REST OF SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 64 REST OF SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 65 REST OF SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 66 REST OF SOUTH AMERICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 67 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 68 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 69 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 70 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 71 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 72 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 73 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 74 ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 75 INDIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 76 INDIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 77 INDIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 78 INDIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 79 INDIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 80 INDIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 81 CHINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 82 CHINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 83 CHINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 84 CHINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 85 CHINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 86 CHINA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 87 JAPAN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 88 JAPAN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 89 JAPAN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 90 JAPAN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 91 JAPAN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 92 JAPAN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 93 SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 94 SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 95 SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 96 SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 97 SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 98 SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 99 AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 100 AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 101 AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 102 AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 103 AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 104 AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 105 SOUTH-EAST ASIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 106 SOUTH-EAST ASIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 107 SOUTH-EAST ASIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 108 SOUTH-EAST ASIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 109 SOUTH-EAST ASIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 110 SOUTH-EAST ASIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 111 REST OF ASIA PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 112 REST OF ASIA PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 113 REST OF ASIA PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 114 REST OF ASIA PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 115 REST OF ASIA PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 116 REST OF ASIA PACIFIC CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 117 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 118 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 119 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 120 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 121 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 122 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 123 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 124 EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 125 GERMANY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 126 GERMANY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 127 GERMANY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 128 GERMANY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 129 GERMANY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 130 GERMANY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 131 UK CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 132 UK CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 133 UK CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 134 UK CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 135 UK CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 136 UK CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 137 FRANCE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 138 FRANCE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 139 FRANCE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 140 FRANCE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 141 FRANCE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 142 FRANCE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 143 ITALY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 144 ITALY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 145 ITALY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 146 ITALY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 147 ITALY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 148 ITALY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 149 SPAIN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 150 SPAIN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 151 SPAIN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 152 SPAIN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 153 SPAIN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 154 SPAIN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 155 RUSSIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 156 RUSSIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 157 RUSSIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 158 RUSSIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 159 RUSSIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 160 RUSSIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 161 REST OF EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 162 REST OF EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 163 REST OF EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 164 REST OF EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 165 REST OF EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 166 REST OF EUROPE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 167 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 168 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 169 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 170 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 171 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 172 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 173 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 174 MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 175 UAE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 176 UAE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 177 UAE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 178 UAE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 179 UAE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 180 UAE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 181 SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 182 SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 183 SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 184 SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 185 SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 186 SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 187 SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 188 SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 189 SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 190 SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 191 SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 192 SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
TABLE 193 REST OF MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
TABLE 194 REST OF MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (THOUSAND UNITS) 2020-2030
TABLE 195 REST OF MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
TABLE 196 REST OF MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (THOUSAND UNITS) 2020-2030
TABLE 197 REST OF MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
TABLE 198 REST OF MIDDLE EAST AND AFRICA CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (THOUSAND UNITS) 2020-2030
LIST OF FIGURES
Â
FIGURE 1 MARKET DYNAMICS
FIGURE 2 MARKET SEGMENTATION
FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4 DATA TRIANGULATION
FIGURE 5 BOTTOM-UP APPROACH
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 RESEARCH FLOW
FIGURE 8 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2020-2030
FIGURE 9 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2020-2030
FIGURE 10 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2020-2030
FIGURE 11 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY REGION (USD BILLION) 2020-2030
FIGURE 12 PORTER’S FIVE FORCES MODEL
FIGURE 13 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY FORM (USD BILLION) 2022
FIGURE 14 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY DRUG CLASS (USD BILLION) 2022
FIGURE 15 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY EMETOGENIK RISK (USD BILLION) 2022
FIGURE 16 GLOBAL CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) DRUGS MARKET BY REGION (USD BILLION) 2022
FIGURE 17 MARKET SHARE ANALYSIS
FIGURE 18 AMNEAL PHARMACEUTICALS: COMPANY SNAPSHOT
FIGURE 19 KYOWA KIRIN: COMPANY SNAPSHOT
FIGURE 20 TESARO: COMPANY SNAPSHOT
FIGURE 21 ACACIA PHARMA: COMPANY SNAPSHOT
FIGURE 22 HERON THERAPEUTICS: COMPANY SNAPSHOT
FIGURE 23 CADILA PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
FIGURE 24 HELSINN HOLDING S.A.: COMPANY SNAPSHOT
FIGURE 25 INSYS THERAPEUTICS: COMPANY SNAPSHOT
FIGURE 26 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
FIGURE 27 MERCK & CO.: COMPANY SNAPSHOT
FIGURE 28 EISAI CO., LTD: COMPANY SNAPSHOT
FIGURE 29 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 30 SANDOZ: COMPANY SNAPSHOT
FIGURE 31 CIPLA LTD: COMPANY SNAPSHOT
FIGURE 32 ORCHID PHARMA LTD: COMPANY SNAPSHOT
FIGURE 33 ADVACARE PHARMA: COMPANY SNAPSHOT
FIGURE 34 MUNDIPHARMA: COMPANY SNAPSHOT
FIGURE 35 CINFA BIOTECH: COMPANY SNAPSHOT
FIGURE 36 ONCOBIOLOGICS: COMPANY SNAPSHOT
FIGURE 37 MYLAN N.V.: COMPANY SNAPSHOT
FAQ
The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size is projected to grow from USD 6.04 billion in 2023 to USD 9.08 billion by 2030, exhibiting a CAGR of 6% during the forecast period.
North America accounted for the largest market in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market.
Amneal Pharmaceuticals, Kyowa Kirin, Tesaro, Acacia Pharma, Heron Therapeutics, Cadila Pharmaceuticals Limited, Helsinn Holding S.A.,Insys Therapeutics, GlaxoSmithKline plc, Merck & Co., Eisai Co., Ltd ,F. Hoffmann-La Roche Ltd.,Sandoz, Cipla Ltd, Orchid Pharma Ltd, AdvaCare Pharma, Mundipharma, Cinfa Biotech, Oncobiologics, Mylan N.V.
Initiatives aiming at raising awareness among healthcare professionals and patients about the importance of CINV treatment for a better understanding and early intervention.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.